Imported from EML workbook.
Formulations: - Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion Indications: - Acute myeloid leukaemia with recurrent genetic abnormalities Source: EML workbook import
Formulations: - Powder for injection: 10 000 IU in vial. Parenteral > General injections > unspecified: 10000 IU in vial powder for injection Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Lymphoid leukaemia, not elsewhere classified Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL Indications: - Chronic lymphocytic leukaemia or small lymphocytic lymphoma - Follicular lymphoma Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate) Indications: - Other specified malignant neoplasms of the ovary - Germ cell tumour of testis - Kaposi sarcoma of unspecified primary site - Hodgkin lymphoma - Unspecified malignant neoplasms of ill-defined or unspecified sites Source: EML workbook import
Formulations: - Oral > Solid: 15 mg tablet Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule Oral > Solid > tablet: 15 mg; 5 mg; 25 mg Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Malignant neoplasm metastasis in large intestine - Burkitt lymphoma including Burkitt leukaemia - Malignant trophoblastic neoplasms of placenta - Osteosarcoma of bone and articular cartilage of unspecified sites - Malignant neoplasms of rectum - Malignant neoplasms of colon Source: EML workbook import
Formulations: - Oral > Solid > tablet: 150 mg; 500 mg Indications: - Malignant neoplasm metastasis in large intestine - Malignant neoplasms of rectum - Malignant neoplasms of colon - Other specified malignant neoplasms of breast Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL Indications: - Other specified malignant neoplasms of bronchus or lung - Other specified gliomas of brain - Malignant neoplasms of nasopharynx - Malignant neoplasms of breast - Osteosarcoma of bone and articular cartilage of unspecified sites - Other specified carcinomas of ovary - Retinoblastoma - Other specified malignant neoplasms of the ovary - Germ cell tumour of testis - Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx - Malignant neoplasms of kidney, except renal pelvis - Malignant neoplasms of cervix uteri - Malignant neoplasms of hypopharynx - Malignant neoplasms of oropharynx Source: EML workbook import
Formulations: - Oral > Solid: 2 mg tablet Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Chronic lymphocytic leukaemia or small lymphocytic lymphoma Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Other specified gliomas of brain - Other specified malignant neoplasms of the ovary - Other specified malignant neoplasms of bronchus or lung - Malignant neoplasms of nasopharynx - Germ cell tumour of testis - Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx - Osteosarcoma of bone and articular cartilage of unspecified sites - Malignant neoplasms of cervix uteri - Malignant neoplasms of hypopharynx - Malignant neoplasms of oropharynx Source: EML workbook import
Formulations: - Oral > Solid: 25 mg tablet Parenteral > General injections > unspecified: 500 mg in vial powder for injection Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Oral > Solid > dosage form: 25 mg; 50 mg Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Other specified malignant neoplasms of breast - Follicular lymphoma - Malignant trophoblastic neoplasms of placenta - Malignant neoplasms of breast - Diffuse large B-cell lymphoma, not otherwise specified - Chronic lymphocytic leukaemia or small lymphocytic lymphoma - Hodgkin lymphoma - Plasma cell myeloma - Other specified gliomas of brain - Burkitt lymphoma including Burkitt leukaemia - Ewing sarcoma of bone and articular cartilage of unspecified sites - Malignant neoplasms of kidney, except renal pelvis - Lymphoid leukaemia, not elsewhere classified - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive - Rhabdomyosarcoma primary site Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 100 mg in vial powder for injection Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Acute myeloid leukaemia with recurrent genetic abnormalities - Burkitt lymphoma including Burkitt leukaemia - Lymphoid leukaemia, not elsewhere classified - Myeloid leukaemia - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive - Langerhans cell histiocytosis Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection Indications: - Hodgkin lymphoma Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.
